Key facts
- This page summarizes Dr. Mark Gold's Form 4 filing for Axogen, Inc. (AXGN).
- 4 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 03 Jun 2022, 16:07.
Dr. Mark Gold - 01 Jun 2022 Form 4 Insider Report for Axogen, Inc. (AXGN)
- Reporting relationship
- Director
- Issuer ticker
- AXGN
- Reported as of
- 01 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2022, 16:07:41 UTC
- Prior SEC filing
- 03 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/Dr. Mark Gold
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Dr. Mark Gold filed Form 4 for Axogen, Inc. (AXGN) on 03 Jun 2022.
Change
- Previous filing in this sequence was filed on 03 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AXGN
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +3,036
- Change %
- +1%
- Price
- $0.000000
- Shares after
- 305,475
- Date
- 01 Jun 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AXGN
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -3,036
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,036
- Exercise price
- Footnotes
- F3, F4
AXGN
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +6,459
- Change %
- Price
- $0.000000
- Shares after
- 6,459
- Date
- 01 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,459
- Exercise price
- Footnotes
- F3, F5
AXGN
transaction
Derivative
Stock Option (right to purchase)
Award
- Transaction value
- $0
- Shares
- +11,811
- Change %
- Price
- $0.000000
- Shares after
- 11,811
- Date
- 01 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,811
- Exercise price
- $9.29
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
This reflects the number of restricted stock units that vested on June 1, 2022.
Footnote F2
The shares of common stock for Dr. Gold include 31,900 shares held directly, 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 22,000 shares held by Dr. Gold's spouse in revocable trusts, and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust.
Footnote F3
Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
Footnote F4
Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.
Footnote F5
Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.